For those of us who live with bipolar disorder, we’re kidding ourselves if we think we can go it alone. While one of the most profound determinants of making a positive recovery is having support from ...

There are two types of bipolar disorder bipolar 1 disorder and bipolar 2 disorder. Bipolar 1 disorder is characterized by moods vacillating between depression and mania. With bipolar 2 disorder, moods ...

Bipolar disorders are currently divided into 4 entities: bipolar I, bipolar II, cyclothymic disorder, and bipolar disorder not otherwise specified, as described in the fourth edition of the ...

Our award-winning bpHope Blog is a collection of posts written with heartfelt honesty by a group of bloggers from around the world, with each providing their own unique perspectives on living with ...

I’ll admit that, despite knowing and loving multiple people with the condition, I had no idea that more people have bipolar than dementia in the UK. But, Bipolar UK tells me, that’s the case ...

Bipolar disorder is a mood disorder that includes at least one manic episode – characterized by elevated or agitated mood and often reduced need for sleep – accompanied by episodes of major ...

SPOKANE, Wash. -- A local woman has turned her 40-year journey with bipolar disorder into a roadmap for teens facing mental health diagnoses. Emalee Gillis, blog editor for the National Alliance ...

Living with bipolar disorder is like riding an emotional roller coaster without a seatbelt. For nearly 40 million people worldwide, the disorder shifts between extremes of euphoria and despair ...

Design Population register-based cohort study with a 20-year follow-up. Setting Sweden. Participants The entire population of Sweden (n=10.6 million) of whom 17 101 persons were diagnosed with bipolar ...

The more common side effects of Caplyta (lumateperone) include sleepiness, nausea or vomiting, fatigue, decreased appetite, dry mouth, and dizziness. These side effects may be temporary and are ...

recommended that the SERENITY At-Home pivotal Phase 3 safety trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia continue without modification.